The European Commission granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA applies to all member states of the European Union, as well as Iceland, Liechtenstein, and Norway. ...
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
Researchers examined the roles of hyperuricemia and anemia in all-cause mortality with chronic kidney disease (CKD).
Outset Medical and US Renal Care have partnered to advance home dialysis with the Outset Tablo Hemodialysis System.
A New Jersey woman with heart and kidney failure received a genetically engineered pig kidney and a mechanical heart pump.
The ERA reviewed phase 3 trials to clarify the mechanism behind HIF-PHi and their role in managing CKD-related anemia.
A bill to improve access to care and outcomes for some dialysis patients was introduced in the House of Representatives.
Research has begun to question recommendations to restrict potassium with CKD to manage hyperkalemia.
Will sparsentan prove a winner for patients with FSGS, or are we doomed to forever treat them with Acthar Gel?
There are few data on whether the survival benefit of kidney transplantation is different for men and women.
American Society of Nephrology leaders met with Congress to urge increased funding to support organ transplantation.
Opinions differ on the use of no anticoagulation versus regional citrate anticoagulation for treatment of AKI with CKRT.
Advertisement
Podcasts
Will sparsentan prove a winner for patients with FSGS, or are we doomed to forever treat them with Acthar Gel?
We've all been guilted into ordering inpatient blood pressure meds. Tim Anderson, MD, asks, "Why?"
Review Dr. Burton Rose's writings on treatment options for hypovolemic states and hypovolemic shock.
In Print
Assessing recurrent gout risk, SARS-CoV-2 vaccine response during dialysis, plant-based diets with CKD, and more.
Special issue discusses racial inequity in living donor kidney transplant, teen BMI and CKD risk, and more
Conferences
The annual scientific, educational, and networking meeting of the International Society of Nephrology
The American Society of Nephrology's annual meeting to highlight the latest scientific and medical advances in the field
The National Kidney Foundation's premier educational event covering advancements in all subspecialties of nephrology
The joint annual meeting of the American Society of Transplantation and the American Society of Transplant Surgeons
Expert Columns
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
The choice of a billing solution, often made under the guise of cost savings, requires a thoughtful approach.
The new base rate for CY 2024 is set at $271.02, which is a 2% increase from CY 2023.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
